GlobeNewswire·Aug 13, 2026, 4:15 PM ET

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

SER

Serina Therapeutics completed enrollment & dosing for all eight patients in Cohort 1 of the SER-252 Phase 1b registrational study in July 2026, ahead of prior guidance.
Top-line data from the single-ascending-dose arm of the SER-252 study is targeted for release in the first half of 2027.
Farrell Simon, Pharm.D., was appointed to the Board of Directors & its Audit & Compensation Committees in July 2026.
A development partnership with Gannet BioChem was established in June 2026 to support process development, scale-up, & manufacturing for SER-252.
Operating expenses for the quarter ended June 30, 2026, were $6.8 million, up from $5.7 million in the same period in 2025.
Research & development expenses increased to $3.8 million for the quarter, driven by higher compensation & increased clinical activity.
General & administrative expenses rose to $3.0 million for the quarter, primarily due to legal expenses related to patent & financing activities.
Other income, net, totaled $0.4 million for the quarter, a $1.3 million increase from the net expense recorded in the prior year period.
Net loss attributable to common shareholders was $8.9 million, or $0.55 per share, for the three months ended June 30, 2026.
Cash & cash equivalents totaled $23.0 million as of June 30, 2026, compared to $3.1 million at the end of 2025.
SER-252 is an investigational apomorphine therapy utilizing the POZ Platform to provide continuous dopaminergic stimulation for Parkinson's disease patients.
The SER-252-1b study is a randomized, double-blind, placebo-controlled trial evaluating safety, tolerability, & pharmacokinetics across sites in the U.S. & Australia.